The Influence of Electronic (ECIG) Heater Resistance on ECIG Acute Effects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03496116 |
|
Recruitment Status :
Completed
First Posted : April 12, 2018
Last Update Posted : May 9, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Nicotine Dependence | Other: ECIG Session | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 38 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Basic Science |
| Official Title: | The Influence of Electronic Cigarette Heater Resistance on Nicotine Delivery, Heart Rate, Subjective Effects and Puff Topography |
| Actual Study Start Date : | May 21, 2018 |
| Actual Primary Completion Date : | December 17, 2018 |
| Actual Study Completion Date : | December 17, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ECIG Session: 0.5 Ohms, 3 mg
Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
|
Other: ECIG Session
Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered. |
|
Experimental: ECIG Session 0.5 Ohms, 8 mg
Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
|
Other: ECIG Session
Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered. |
|
Experimental: ECIG Session 1.5 Ohms, 3 mg
Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
|
Other: ECIG Session
Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered. |
|
Experimental: ECIG Session 1.5 Ohms, 8 mg
Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
|
Other: ECIG Session
Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered. |
- Cmax: Plasma nicotine concentration (ng/ml) [ Time Frame: Six blood samples are collected at each of the 4 visits. During each session, blood samples are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]
- Withdrawal suppression: Hughes-Hatsukami Withdrawal Scale [ Time Frame: Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]Contains 11 items. Administered on a computerized visual analogue scale that consists of a phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right.. Responses range from 0-100.
- Withdrawal suppression: Direct effects of nicotine scale [ Time Frame: Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]Contains 9-items. Administered on a computerized visual analogue scale that consists of a phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right.. Responses range from 0-100.
- Withdrawal suppression: Tiffany Drobes Questionnaire of Smoking Urges [ Time Frame: Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]Contains 10 items. Participants will be asked to rate each phrase on a 7-point scale ranging from 0 (Strongly disagree) to 7 (Strongly agree). The items from this scale will form two factors: Factor 1 (intention to smoke) and Factor 2 (anticipation of relief from abstinence symptoms).
- Withdrawal suppression: Direct effects of ECIG use scale [ Time Frame: Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]Contains 14-items. Administered on a computerized visual analogue scale that consists of a phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right. Responses range from 0-100.
- Other subjective effects: General Labeled Magnitude Scale [ Time Frame: Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]Contains 4-items. This category-ratio scale contains seven semantic labels that increase in sensitivity including: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable sensation of any kind." Responses will be coded on a 0-100 scale.
- Other subjective effects: Labeled Hedonic Scale [ Time Frame: Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours. ]Contains 4-items. This category-ratio scale contains ten semantic labels, intended to assess participant liking or disliking of sensations experienced in the general labeled magnitude scale.. Semantic labels include: "most liked sensation imaginable", "like extremely", "like very much", "like moderately", "like slightly", "dislike slightly", "dislike moderately", "dislike very much", "dislike extremely" and "most disliked sensation imaginable". Responses will be coded on a 0-100 scale.
- Puff Topography: puff duration [ Time Frame: Collected twice at each of the 4 visits. During each session, puff duration is measured at 95 and 225 minutes. ]Puff duration is the measurement of the length of participant puffs in seconds during a 10-puff directed puffing bout (lasting 5-minutes) and during the 60-minute ad libitum bout where participants are instructed to puff as much or as little as they like on the ECIG.
- Puff Topography: puff volume [ Time Frame: Collected twice at each of the 4 visits. During each session, puff duration is measured at 95 and 225 minutes. ]Puff volume is the measurement of the size of participant puffs in milliliters during a 10-puff directed puffing bout (lasting 5-minutes) and during the 60-minute ad libitum bout where participants are instructed to puff as much or as little as they like on the ECIG.
- Puff Topography: puff velocity [ Time Frame: Collected twice at each of the 4 visits. During each session, puff duration is measured at 95 and 225 minutes. ]Puff velocity is the measurement of the speed of participant puffs in milliliters per second during a 10-puff directed puffing bout (lasting 5-minutes) and during the 60-minute ad libitum bout where participants are instructed to puff as much or as little as they like on the ECIG.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Willing to provide informed consent, attend the lab and abstain from nicotine/tobacco as required, and use designated products according to study protocol
- Experienced ECIG users (use ≥1 ml of ECIG solution daily, use ECIG solution with a nicotine concentration ≥3 mg/ml, and have used their ECIG for ≥3 months)
- Urine cotinine test result ≥ 3
Exclusion Criteria:
- History of organ-related diseases or current psychiatric condition
- Regular use of prescription medication other than vitamins or birth control
- Past month use of cocaine, opioids, benzodiazepines, or methamphetamine
- Using marijuana greater than 10 days in the past 30 and/or alcohol greater than 25 days in the past 30 days
- Pregnant or breastfeeding women
- Weight less than 110 pounds
- Daily use of >5 cigarettes or use of other tobacco products (i.e., hookah, cigars) >3 times a week
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03496116
| United States, Virginia | |
| Virginia Commonwealth University | |
| Richmond, Virginia, United States, 23298 | |
| Principal Investigator: | Thomas E Eissenberg, PhD | Virginia Commonwealth University |
| Responsible Party: | Virginia Commonwealth University |
| ClinicalTrials.gov Identifier: | NCT03496116 |
| Other Study ID Numbers: |
HM20012671 |
| First Posted: | April 12, 2018 Key Record Dates |
| Last Update Posted: | May 9, 2019 |
| Last Verified: | May 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Tobacco Use Disorder Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |

